3-氟吡啶-4-醇 | 22282-73-1

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氟吡啶-4-醇
• 中文别名: 3-氟-4-羟基吡啶
• 英文名称: 3-fluoropyridin-4-ol
• 英文别名: 3-fluoro-1H-pyridin-4-one
• CAS: 22282-73-1
• 化学式: C₅H₄FNO
• mdl: MFCD04114240
• 分子量: 113.091
• InChiKey: HTXNVGYNXOGIQZ-UHFFFAOYSA-N

物化性质

• 熔点：
  153 °C
• 沸点：
  315.8±22.0 °C(Predicted)
• 密度：
  1.325±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-氟吡啶-4-醇 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-溴-5-氟-4-羟基吡啶
  参考文献：
  名称：

  [EN] STAT MODULATORS AND USES THEREOF
  [FR] MODULATEURS DE STAT ET LEURS UTILISATIONS

  摘要：

  Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6.

  公开号：

  WO2023133336A1
• 作为产物：
  描述：

  3-氟吡啶-4-硼酸 在 copper(ll) sulfate pentahydrate 、 鞣花酸 作用下， 以 甲醇 为溶剂， 60.0 ℃ 、101.33 kPa 条件下， 反应 8.0h， 以75%的产率得到3-氟吡啶-4-醇
  参考文献：
  名称：

  Oxidative hydroxylation of arylboronic acids to phenols catalyzed by copper nanoparticles ellagic acid composite

  摘要：

  Copper nanoparticles (Cu NPs) were prepared by in situ reduction of CuSO4 center dot 5H(2)O using ellagic acid (EA) as the reducing agent as well as stabilizer and its catalytic activity is tested in the oxidative hydroxylation of phenylboronic acids to phenol without any added base or ligand. The synthesized Cu NPs-EA composite was characterized by UV-Vis., FT-IR, powder XRD and HRTEM analyses. The average particle size of Cu NPs is found to be in the range of 20-25 nm as evident from HRTEM and copper content is estimated to be 3.18 wt%. EA acts both as a reducing agent as well as a stabilizer for the in situ formation of Cu NPs. A small portion of Cu NPs is also found to undergo aerobic oxidation to give Cu2O NPs which does not take part in the reactions. A series of arylboronic acids are converted to the corresponding phenols in high yields at short reaction time under milder reaction conditions. It is also observed that Cu NPs-EA composite can be reused at least four times with a significant decrease in the yield. (C) 2014 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molcata.2014.09.016

文献信息

• MODIFIED COMPOUND OF ANDROGRAPHOLIDE
  申请人：Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

  公开号：US20180346438A1

  公开（公告）日：2018-12-06

  The present disclosure discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof.

  本公开披露了穿心莲内酯的修改化合物，特别是公开了公式(I)和(II)所示的化合物或其药用可接受的盐。
• Oxopyridinylquinoxaline derivative
  申请人：Shionogi & Co., Ltd.

  公开号：US05677305A1

  公开（公告）日：1997-10-14

  An oxopyridinylquinoxaline derivative represented by the following Formula I or pharmaceutically acceptable salts thereof: ##STR1## wherein R.sup.1 is hydrogen, halogen, nitro, or trihalomethyl; R.sup.2 is hydrogen, halogen, nitro, cyano, trihalomethyl, carbamoyl, carbamoyl substituted with lower alkyl, sulfamoyl, or sulfamoyl substituted with lower alkyl; R.sup.3 is hydrogen, nitro, or halogen; R.sup.4 is hydrogen, lower alkyl, substituted lower alkyl, lower cycloalkyl, or substituted lower cycloalkyl; R.sup.5 's are substituents independently selected from the group consisting of halogen, nitro, cyano, lower alkyl, carbamoyl, and carbamoyl substituted with lower alkyl; and n is an integer of 0 to 4. The derivative works as an antagonistic agent against both the NMDA receptors and the AMPA receptors, so that it is effective as a therapeutic agent for neurological disorders caused by excitatory amino acids binding to the receptors.

  一种由以下化学式I表示的氧吡啶基喹喔啉衍生物或其药用盐：##STR1##其中R.sup.1为氢、卤素、硝基或三卤甲基；R.sup.2为氢、卤素、硝基、氰基、三卤甲基、氨基甲酰基、带有较低烷基取代的氨基甲酰基、磺胺基或带有较低烷基取代的磺胺基；R.sup.3为氢、硝基或卤素；R.sup.4为氢、较低烷基、取代的较低烷基、较低环烷基或取代的较低环烷基；R.sup.5'为从卤素、硝基、氰基、较低烷基、氨基甲酰基和带有较低烷基取代的氨基甲酰基组成的基团中独立选择的取代基；n为0到4的整数。该衍生物作为对NMDA受体和AMPA受体的拮抗剂，因此对由兴奋性氨基酸结合到受体引起的神经系统疾病具有治疗作用。
• Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2
  作者：Andrew S. Felts、Alice L. Rodriguez、Katrina A. Smith、Julie L. Engers、Ryan D. Morrison、Frank W. Byers、Anna L. Blobaum、Charles W. Locuson、Sichen Chang、Daryl F. Venable、Colleen M. Niswender、J. Scott Daniels、P. Jeffrey Conn、Craig W. Lindsley、Kyle A. Emmitte

  DOI：10.1021/acs.jmedchem.5b01371

  日期：2015.11.25

  selective mGlu2 negative allosteric modulator 58 (VU6001192) from a series of 4-oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides. The concept for the design of this series centered on morphing a quinoline series recently disclosed in the patent literature into a chemotype previously used for the preparation of muscarinic acetylcholine receptor subtype 1 positive allosteric modulators. Compound 58 exhibits

  II组代谢型谷氨酸受体（mGlus）的正构和变构拮抗剂都已被用于建立mGlu2 / 3抑制与多种中枢神经系统疾病和病症之间的联系。尽管与mGlu家族的其余六个成员相比，这些工具通常对mGlu2 / 3具有良好的选择性，但事实证明，仅对单独的II类mGlus之一具有选择性的化合物。在本文中，我们报道了从一系列4-氧-1-芳基-1,4-二氢喹啉-3-羧酰胺中发现的有效且高度选择性的mGlu2负变构调节剂58（VU6001192）。该系列的设计思想集中在将专利文献中最近公开的喹啉系列转变为先前用于制备毒蕈碱型乙酰胆碱受体亚型1阳性变构调节剂的化学型。化合物58表现出良好的特性，将成为了解选择性抑制CNS中mGlu2的生物学意义的有用工具。
• 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, addition salts thereof, and processes for the preparation of both
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：US06348461B1

  公开（公告）日：2002-02-19

  The present invention provides 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid compounds and their addition salts, and processes for preparing them, which have antagonism against excitatory amino acid receptors, in particular, an AMPA receptor. The 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid compounds and their addition salts of the present invention are represented by formula (1) wherein Q, R, R1 and R2 are as described in the specification.

  本发明提供了6,7-不对称二取代喹喔啉羧酸化合物及其加合盐，以及制备它们的方法，这些化合物对兴奋性氨基酸受体，特别是AMPA受体具有拮抗作用。本发明的6,7-不对称二取代喹喔啉羧酸化合物及其加合盐由下式表示（1式），其中Q、R、R1和R2如规范中所述。
• [EN] BICYCLIC INHIBITORS OF ALK<br/>[FR] INHIBITEURS BICYCLIQUES DE L'ALK
  申请人：ABBOTT LAB

  公开号：WO2012097682A1

  公开（公告）日：2012-07-26

  The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

  本发明涉及公式（1）的化合物或药用可接受的盐，其中R1、X、Y、Z、A、B、G1和n在描述中有定义。本发明还涉及含有上述化合物的组合物，用于抑制蛋白激酶如ALK并治疗癌症等疾病的方法。